x
Breaking News
0

Gilead Sciences Inc (GILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Gilead's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
79.95 -1.22    -1.50%
16/10 - Closed. Currency in USD ( Disclaimer )
After Hours
79.99
+0.04
+0.05%
16/10
Type: Equity
Market: United States
ISIN: US3755581036 
CUSIP: 375558103
  • Volume: 7,377,562
  • Bid/Ask: 79.90 / 79.99
  • Day's Range: 79.55 - 81.21
Start Trading with Nadex
Gilead 79.95 -1.22 -1.50%

GILD Overview

 
Information about the Gilead Sciences Inc Stock. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close81.17
Day's Range79.55 - 81.21
Revenue28.47B
Open81.13
52 wk Range63.76 - 86.27
EPS9.21
Volume7,377,562
Market Cap106B
Dividend (Yield)1.98 (2.56%)
Average Vol. (3m)8,708,049
P/E Ratio8.81
Beta1.17
1-Year Change9.9%
Shares Outstanding1,305,926,217
Next Earnings DateOct 26, 2017

Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Strong Sell Strong Sell Strong Sell Neutral Buy
Technical Indicators Strong Sell Strong Sell Strong Sell Strong Sell Strong Buy
Summary Strong Sell Strong Sell Strong Sell Sell Strong Buy

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Completed Patterns
Morning Doji Star 1H 1 Oct 16, 2017 02:00PM
Falling Three Methods 1D 2 Oct 12, 2017
Bullish doji Star 1H 2 Oct 16, 2017 01:00PM
Bullish Engulfing 1D 4 Oct 10, 2017
Engulfing Bearish 1W 5 Sep 10, 2017

Gilead Sciences Inc News & Analysis

Gilead Sciences Inc Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 79.95 79.90 79.99 7,377,562 -1.50% USD 16/10  
  Mexico 1,520.90 1,522.00 1,559.00 138 -0.85% MXN 16/10  
  Switzerland 80.150 72.000 104.400 0 0.00% CHF 13/10  
  Switzerland 83.150 0.000 0.000 0 0.00% USD 15/09  
  Frankfurt 67.42 0.00 0.00 3,989 -1.34% EUR 16/10  
  Berlin 68.900 67.470 67.570 0 +0.54% EUR 16/10  
  TradeGate 67.73 67.71 67.87 9,324 -1.45% EUR 16/10  
  Munich 69.020 0.000 0.000 89 +0.74% EUR 16/10  
  Stuttgart 67.520 0.000 0.000 283 -1.08% EUR 16/10  
  Vienna 68.460 0.000 0.000 707 +0.03% EUR 16/10  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Netflix 202.68 202.83 197.86 +3.19 +1.60% 22.11M 16/10  
  Apple 159.88 160.00 157.65 +2.89 +1.84% 24.12M 16/10  
  NVIDIA 197.93 198.05 193.24 +3.34 +1.72% 14.42M 16/10  
  Alibaba 179.56 180.05 178.51 +1.11 +0.62% 12.86M 16/10  
  Tesla 350.60 354.48 347.16 -4.97 -1.40% 5.38M 16/10  
  Facebook 174.52 175.00 174.06 +0.78 +0.45% 11.50M 16/10  
  Amazon.com 1,006.34 1,009.57 1,001.04 +3.40 +0.34% 2.01M 16/10  
  Micron 41.49 41.57 40.51 +1.09 +2.70% 33.70M 16/10  
  AMD 14.260 14.350 14.120 +0.040 +0.28% 34.14M 16/10  
  Transenterix Inc 2.8100 3.0500 2.1500 +1.3500 +92.47% 80.58M 16/10  

Gilead Sciences Inc Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

9000

Equity Type

ORD

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
National Futures Association (United States), National Securities Depository (India), U.S. Commodity Futures Trading Commission (United States), The Financial Conduct Authority (United Kingdom), Financial Industry Regulatory Authority (United States), Investment Industry Regulatory Organization of Canada (Canada), Securities and Exchange Board of India (India), Securities and Exchange Commission (United States), The Securities and Futures Commission (Hong Kong), Securities Investor Protection Corporation (United States) $10000 Start Trading
U.S. Commodity Futures Trading Commission (United States) $250 Start Trading
U.S. Commodity Futures Trading Commission (United States) Start Trading
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) Start Trading

My Sentiments

What is your sentiment on Gilead?
or
Market is currently closed. Voting is open during market hours.

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

 
Are you sure you want to delete this chart?
 
Write your thoughts about Gilead Sciences Inc
 
Replace the attached chart with a new chart ?
Post
Post also to:
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

Latest GILD Comments

Episcopolian OptionTrader
Episcopolian1 Oct 02, 2017 5:11PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$GILD The NASH Phase 2 data release iis now delayed until end-of-the-yea, possibly 1st qtr of 2018. Not good! but very good sign for $ICPT
Reply
0 0
Episcopolian OptionTrader
Episcopolian1 Oct 03, 2017 2:10PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sell $GILD and buy $ICPT
Reply
0 0
Episcopolian OptionTrader
Episcopolian1 Sep 28, 2017 2:08PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Floor chatter about Phase 2 NASH has failed!
Reply
0 0
Episcopolian OptionTrader
Episcopolian1 Sep 28, 2017 2:02PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A bad feeling about $GILD's COO retirement announcement, right before NASH announcement!!!
Reply
0 0
Show more comments
 
Are you sure you want to delete this chart?
 
 
Replace the attached chart with a new chart ?
Post 1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
 
 
 
Add Chart to Comment
Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email